ABSTRACT
Antimalarials have been used in dermatology for the management of cutaneous lupus erythematosus and connective tissue diseases (2). Other diseases treated with these agents include polymorphous light eruption, cutaneous sarcoidosis, and porphyria cutanea tarda. In the past, chloroquine was the primary antimalarial used in dermatology, and its adverse effects have been reviewed elsewhere (3). Currently, the antimalarial of fi rst choice, at least in the treatment of cutaneous lupus, appears to be hydroxychloroquine (4). This drug tends to be viewed as the safest antimalarial, without any obvious difference in effi cacy from other antimalarials (2).
